Biomarker Testing in NSCLC - Text Module - Testing Before Treating in ...
Drs Matthew Gubens and Craig Mackinnon discuss biomarker testing and treatment strategies for patients with NSCLC in a focused, expert-authored module from Clinical Care Options (CCO)
Interferons for HDV Treatment | CCO - clinicaloptions.com
As a nationally recognized provider of continuing education for healthcare professionals, CCO develops, delivers, and evaluates a broad range of accredited, cutting-edge CME and CE opportunities.
Barriers to HIV Care | CCO - clinicaloptions.com
As a nationally recognized provider of continuing education for healthcare professionals, CCO develops, delivers, and evaluates a broad range of accredited, cutting-edge CME and CE opportunities.
A Look to the Future: Novel Agents and Combination Regimens | CCO
Dec 4, 2024 · Download this slideset from a live symposium at ASH 2024 for expert perspectives on emerging strategies in treating patients with relapsed/refractory CLL.
Rela/Nivo 1L Melanoma - ClinicalThought - LAG3Local2022 | CCO
In this commentary from Clinical Care Options (CCO), Dr. Evan Lipson reviews data on relatlimab plus nivolumab in melanoma from the RELATIVITY-047 trial
CCO Independent Conference Highlights*of the 2022 ASCO Annual Meeting, June 3-7, 2022, Chicago, Illinois *CCO is an independent medical education company that provides state-of-the-art medical …
Disclaimer: The materials published on the Clinical Care Options website reflect the views of the authors of the CCO material, not those of Clinical Care Options, LLC, the CME providers, or the companies …
| CCO
CCO It looks like something went wrong. The page you are looking for may have been moved or the URL you entered may not be correct.